memantine.com - Memantine protects hippocampal neuronal function in ...
Anderson ER, Gendelman HE, Xiong H (2004). JAMA, 291 (3): 317-24. Memantine, a low-to-moderate-affinity NMDA receptor antagonist, can be used to ...
News - Extended-Release Memantine Improves Verbal Communication and ...
Extended-Release Memantine Improves Verbal Communication and Behaviour in ... Previous studies suggested that ER memantine is effective and well tolerated, ...
Cognitive Symptoms
... an "extended release" form as Razadyne ER that is designed to be taken ... Those receiving memantine showed a small but statistically significant benefit ...
Memantine - Pubdrug
Memantine slows the rate of clinical deterioration in patients with moderate to ... ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment ...
LE Magazine, May 2004 - As We See It: FDA Approves Deadly Drugs, Delays ...
... Extension has long recommended it to family members of Alzheim-er's victims.49. Memantine does not offer miraculous benefits. ...
memantine.com - Weitere Literatur 2001
Co-administration of memantine and amantadine with sub/suprathreshold doses of ... Linden AM, Vasanen J, Storvik M, Lakso M, Korpi ER, Wong G, Castren E (2001) ...
IngentaConnect Search Results
Memantine for prophylaxis of chronic tension-type headache—a double-blind, ... Memorable results for memantine ER in Alzheimer's disease ...
MEDLINE Search on Medscape.com
Search Medscape's physician ... NAMENDA® (memantine HCl) InfoSite ... Zhongguo Dang Dai Er Ke Za Zhi, February 2006. Refine Your Results. 1 - 10 of 1,165 ...
Alabama Medicaid Agency Pharmacy and Therapeutics Committee Meeting
Razadyne ER. NMDA Receptor Antagonist. Memantine. Oral. Namenda ... Memantine is ... levels, which are lower with the ER version. ...
Alzheimer's Disease Causes, Symptoms, Diagnosis, and Treatment by ...
galantamine, Razadyne, Razadyne ER. GALANTAMINE-ORAL, Razadyne, Reminyl ... MEMANTINE-ORAL, Namenda. RISPERIDONE-ORAL, Risperdal. RISPERIDONE-INJECTION, ...
|
CiteULike: Memantine for dementia.
Register |
Log in
| FAQ
CiteULike is a free online bibliography manager. Register
and you can start organising your references online.BACKGROUND: Alzheimer's disease, vascular and mixed dementia are the commonest forms of dementia in older people. There is evidence that the excitatory activity of L-glutamate plays a role in the pathogenesis of Alzheimer's disease and in the damage from an ischaemic stroke. A low affinity antagonist to N-Methyl-D-aspartate (NMDA) type receptors, such as memantine, may prevent excitatory amino acid neurotoxicity without interfering with the physiological actions of glutamate required for memory and learning. OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, vascular, or mixed dementia.